Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Endocrinology ; 147(2): 1044-53, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16269450

ABSTRACT

Specific retinoid X receptor (RXR) agonists, such as LG100268 (LG268), and the thiazolidinedione (TZD) PPARgamma agonists, such as rosiglitazone, produce insulin sensitization in rodent models of insulin resistance and type 2 diabetes. In sharp contrast to the TZDs that produce significant increases in body weight gain, RXR agonists reduce body weight gain and food consumption. Unfortunately, RXR agonists also suppress the thyroid hormone axis and generally produce hypertriglyceridemia. Heterodimer-selective RXR modulators have been identified that, in rodents, retain the metabolic benefits of RXR agonists with reduced side effects. These modulators bind specifically to RXR with high affinity and are RXR homodimer partial agonists. Although RXR agonists activate many heterodimer partners, these modulators selectively activate RXR:PPARalpha and RXR:PPARgamma, but not RXR:RARalpha, RXR:LXRalpha, RXR:LXRbeta, or RXR:FXRalpha. We report the in vivo characterization of one RXR modulator, LG101506 (LG1506). In Zucker fatty (fa/fa) rats, LG1506 is a potent insulin sensitizer that also enhances the insulin-sensitizing activities of rosiglitazone. Administration of LG1506 reduces both body weight gain and food consumption and blocks the TZD-induced weight gain when coadministered with rosiglitazone. LG1506 does not significantly suppress the thyroid hormone axis in rats, nor does it elevate triglycerides in Sprague Dawley rats. However, LG1506 produces a unique pattern of triglycerides elevation in Zucker rats. LG1506 elevates high-density lipoprotein cholesterol in humanized apolipoprotein A-1-transgenic mice. Therefore, selective RXR modulators are a promising approach for developing improved therapies for type 2 diabetes, although additional studies are needed to understand the strain-specific effects on triglycerides.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Fatty Acids, Unsaturated/administration & dosage , Hypoglycemic Agents/administration & dosage , Obesity/drug therapy , Phenyl Ethers/administration & dosage , Retinoid X Receptors/agonists , Thiazolidinediones/administration & dosage , Analysis of Variance , Animals , Apolipoprotein A-I/genetics , Apolipoprotein A-I/physiology , Area Under Curve , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/complications , Dose-Response Relationship, Drug , Drug Interactions , Female , Hypoglycemic Agents/therapeutic use , Mice , Mice, Transgenic , Obesity/blood , Obesity/complications , PPAR gamma/agonists , PPAR gamma/metabolism , Rats , Rats, Sprague-Dawley , Rats, Zucker , Retinoid X Receptors/metabolism , Rosiglitazone , Statistics, Nonparametric , Thiazolidinediones/pharmacology , Thiazolidinediones/therapeutic use , Thyroid Gland/drug effects , Triglycerides/blood
2.
Mol Endocrinol ; 19(6): 1593-605, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15831517

ABSTRACT

LSN862 is a novel peroxisome proliferator-activated receptor (PPAR)alpha/gamma dual agonist with a unique in vitro profile that shows improvements on glucose and lipid levels in rodent models of type 2 diabetes and dyslipidemia. Data from in vitro binding, cotransfection, and cofactor recruitment assays characterize LSN862 as a high-affinity PPARgamma partial agonist with relatively less but significant PPARalpha agonist activity. Using these same assays, rosiglitazone was characterized as a high-affinity PPARgamma full agonist with no PPARalpha activity. When administered to Zucker diabetic fatty rats, LSN862 displayed significant glucose and triglyceride lowering and a significantly greater increase in adiponectin levels compared with rosiglitazone. Expression of genes involved in metabolic pathways in the liver and in two fat depots from compound-treated Zucker diabetic fatty rats was evaluated. Only LSN862 significantly elevated mRNA levels of pyruvate dehydrogenase kinase isozyme 4 and bifunctional enzyme in the liver and lipoprotein lipase in both fat depots. In contrast, both LSN862 and rosiglitazone decreased phosphoenol pyruvate carboxykinase in the liver and increased malic enzyme mRNA levels in the fat. In addition, LSN862 was examined in a second rodent model of type 2 diabetes, db/db mice. In this study, LSN862 demonstrated statistically better antidiabetic efficacy compared with rosiglitazone with an equivalent side effect profile. LSN862, rosiglitazone, and fenofibrate were each evaluated in the humanized apoA1 transgenic mouse. At the highest dose administered, LSN862 and fenofibrate reduced very low-density lipoprotein cholesterol, whereas, rosiglitazone increased very low-density lipoprotein cholesterol. LSN862, fenofibrate, and rosiglitazone produced maximal increases in high-density lipoprotein cholesterol of 65, 54, and 30%, respectively. These findings show that PPARgamma full agonist activity is not necessary to achieve potent and efficacious insulin-sensitizing benefits and demonstrate the therapeutic advantages of a PPARalpha/gamma dual agonist.


Subject(s)
Alkynes/pharmacology , Cinnamates/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Hyperlipidemias/drug therapy , PPAR alpha/agonists , PPAR alpha/metabolism , PPAR gamma/agonists , PPAR gamma/metabolism , Adiponectin , Alkynes/chemistry , Animals , Binding, Competitive , Body Weight , Cholesterol/metabolism , Cholesterol, HDL/metabolism , Cholesterol, VLDL/metabolism , Cinnamates/chemistry , Diabetes Mellitus, Type 2/metabolism , Dose-Response Relationship, Drug , Fenofibrate/pharmacology , Gene Expression Regulation, Enzymologic , Glucose/metabolism , Homozygote , Humans , Hyperlipidemias/metabolism , In Vitro Techniques , Insulin/metabolism , Intercellular Signaling Peptides and Proteins/metabolism , Kinetics , Lipid Metabolism , Liver/enzymology , Male , Mice , Mice, Transgenic , Models, Chemical , Protein Binding , Protein Isoforms , RNA, Messenger/metabolism , Rats , Rosiglitazone , Thiazolidinediones/pharmacology , Transfection , Triglycerides/metabolism , Two-Hybrid System Techniques
3.
J Biol Chem ; 279(23): 23908-15, 2004 Jun 04.
Article in English | MEDLINE | ID: mdl-15073165

ABSTRACT

Insulin-induced gene 1 (INSIG-1) is a key regulator in the processing of the sterol regulatory element-binding proteins (SREBPs). We demonstrated that Insig-1 is regulated by peroxisome proliferator-activated receptor gamma (PPARgamma) providing a link between insulin sensitization/glucose homeostasis and lipid homeostasis. Insig-1 was identified as a PPARgamma target gene using microarray analysis of mRNA from the white adipose tissue of diabetic (db/db) animals treated with PPARgamma agonists. Insig-1 was induced in subcutaneous (9-fold) and epididymal (4-fold) fat pads from db/db mice treated for 8 days with the PPARgamma agonist rosiglitazone (30 mg/kg/day). This in vivo response was confirmed in differentiated C3H10T1/2 adipocytes treated with rosiglitazone. To elucidate the molecular mechanisms regulating INSIG-1 expression, we cloned and characterized the human INSIG-1 promoter. Co-expression of PPARgamma and RXRalpha transactivated the INSIG-1 promoter in the presence of PPARgamma agonists. This induction was attenuated when a dominant negative PPARgamma construct was transfected into cells. Furthermore, a PPARgamma antagonist repressed the transactivation of the INSIG-1 promoter-reporter construct. Truncations of the promoter resulted in the identification of a PPAR response element that mediated the regulation of the promoter. We demonstrated with recombinant proteins that the PPARgamma/RXRalpha heterodimer binds directly to this PPAR response element. In addition to regulation by PPARgamma/RXRalpha, we demonstrated that the INSIG-1 promoter is regulated by transcriptionally active SREBP. The sterol response element was identified 380 base pairs upstream of the transcriptional start site. These findings suggest that the regulation of Insig-1 by PPARgamma agonists could in turn regulate SREBP processing and thus couple insulin sensitizers with the regulation of lipid homeostasis.


Subject(s)
Adipocytes/metabolism , Adipose Tissue/metabolism , CCAAT-Enhancer-Binding Proteins/biosynthesis , DNA-Binding Proteins/biosynthesis , Membrane Proteins/biosynthesis , Receptors, Cytoplasmic and Nuclear/metabolism , Thiazolidinediones/pharmacology , Transcription Factors/metabolism , Animals , Cells, Cultured , DNA, Complementary/metabolism , Dose-Response Relationship, Drug , Epididymis/metabolism , Gene Expression Regulation , Genes, Reporter , Hypoglycemic Agents/pharmacology , Insulin/metabolism , Intracellular Signaling Peptides and Proteins , Lipid Metabolism , Liver/metabolism , Male , Mice , Mice, Inbred C3H , Models, Biological , Oligonucleotide Array Sequence Analysis , Promoter Regions, Genetic , Protein Binding , RNA/metabolism , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Rosiglitazone , Sterol Regulatory Element Binding Protein 1 , Time Factors , Transcription, Genetic , Transcriptional Activation , Transfection
5.
Endocrinology ; 143(8): 2880-5, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12130551

ABSTRACT

The retinoid X receptor (RXR) agonist bexarotene can cause clinically significant hypothyroidism in cutaneous T cell lymphoma patients. The mechanism by which the RXR agonist produces this effect is unclear. We have studied the impact of a selective RXR agonist (rexinoid), LG100268, on rat thyroid axis hormones and show that the acute phase of hypothyroidism is associated with reduced pituitary TSH secretion. A single oral administration of LG100268 to naive Sprague Dawley rats causes a rapid and statistically significant decline in TSH levels (apparent in 0.5-1 h). Total T(4) and T(3) levels decline more gradually, reaching statistical significance 24 h after treatment. Increasing doses of LG100268 produce greater suppression of thyroid axis hormones. To investigate the mechanism(s) mediating this suppression, we determined pituitary TSHbeta mRNA, TSH protein levels, and TRH-stimulated TSH secretion. Two hours after treatment, neither TSHbeta mRNA nor TSH protein levels were altered by LG100268. However, LG100268 treatment reduced the area under the curve for TRH-stimulated TSH secretion by 54%. We have identified an unexpected mechanism by which rexinoids induce hypothyroidism by acutely reducing TSH secretion from the anterior pituitary. This mechanism is independent of the rexinoid's previously demonstrated inhibition of TSHbeta gene transcription.


Subject(s)
Hypothyroidism/chemically induced , Nicotinic Acids/pharmacology , Receptors, Retinoic Acid/physiology , Tetrahydronaphthalenes/pharmacology , Transcription Factors/physiology , Animals , Male , RNA, Messenger/analysis , Rats , Rats, Sprague-Dawley , Receptors, Retinoic Acid/agonists , Retinoid X Receptors , Thyroid Hormones/blood , Thyrotropin/blood , Thyrotropin/genetics , Transcription Factors/agonists
SELECTION OF CITATIONS
SEARCH DETAIL
...